Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 3
1976 5
1977 6
1978 4
1979 3
1980 3
1981 3
1982 2
1983 6
1984 2
1985 7
1986 3
1987 4
1988 3
1989 3
1990 1
1991 3
1992 1
1994 7
1995 4
1997 1
1998 3
2000 1
2003 3
2004 6
2005 3
2006 8
2007 4
2008 5
2009 4
2010 3
2011 2
2012 3
2013 4
2014 1
2015 2
2016 4
2017 8
2018 5
2019 8
2020 9
2021 8
2022 7
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie DH, Boriani G, Camm AJ, Conen D, Erath JW, Gold MR, Hohnloser SH, Ip J, Kautzner J, Kutyifa V, Linde C, Mabo P, Mairesse G, Benezet Mazuecos J, Cosedis Nielsen J, Philippon F, Proietti M, Sticherling C, Wong JA, Wright DJ, Zarraga IG, Coutts SB, Kaplan A, Pombo M, Ayala-Paredes F, Xu L, Simek K, Nevills S, Mian R, Connolly SJ; ARTESIA Investigators. Healey JS, et al. N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12. N Engl J Med. 2024. PMID: 37952132 Clinical Trial.
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. Mateos MV, et al. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):385-393. doi: 10.1016/j.clml.2023.02.006. Epub 2023 Mar 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36967244 Clinical Trial.
An APRI+ALBI Based Multivariable Model as Preoperative Predictor for Posthepatectomy Liver Failure.
Santol J, Kim S, Gregory LA, Baumgartner R, Murtha-Lemekhova A, Birgin E, Gloor S, Braunwarth E, Ammann M, Starlinger J, Pereyra D, Ammon D, Ninkovic M, Kern AE, Rumpf B, Ortmayr G, Herrmann Y, Dong Y, Huber FX, Weninger J, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Nagorney DN, Cleary SP, Beldi G, Rahbari NN, Hoffmann K, Gilg S, Assinger A, Gruenberger T, Hackl H, Starlinger P. Santol J, et al. Ann Surg. 2023 Oct 20. doi: 10.1097/SLA.0000000000006127. Online ahead of print. Ann Surg. 2023. PMID: 37860868 Free article.
OBJECTIVE AND BACKGROUND: Clinically significant posthepatectomy liver failure (PHLF B+C) remains the main cause of mortality after major hepatic resection. ...RESULTS: A MVM including APRI+ALBI, age, sex, tumor type and extent of resection was found to predict PHLF B
OBJECTIVE AND BACKGROUND: Clinically significant posthepatectomy liver failure (PHLF B+C) remains the main cause of mortality after m …
Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan FP, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Jeger RV, et al. Lancet. 2018 Sep 8;392(10150):849-856. doi: 10.1016/S0140-6736(18)31719-7. Epub 2018 Aug 28. Lancet. 2018. PMID: 30170854 Free article. Clinical Trial.
FUNDING: Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung, Basel Cardiovascular Research Foundation, and B Braun Medical AG....
FUNDING: Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung, Basel Cardiovascular Research Foundation, and B
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Jeger RV, et al. Lancet. 2020 Nov 7;396(10261):1504-1510. doi: 10.1016/S0140-6736(20)32173-5. Epub 2020 Oct 19. Lancet. 2020. PMID: 33091360 Clinical Trial.
FUNDING: Swiss National Science Foundation, Basel Cardiovascular Research Foundation, and B Braun Medical....
FUNDING: Swiss National Science Foundation, Basel Cardiovascular Research Foundation, and B Braun Medical....
The current status of virus-positive liver transplantation.
Delman AM, Ammann AM, Shah SA. Delman AM, et al. Curr Opin Organ Transplant. 2021 Apr 1;26(2):160-167. doi: 10.1097/MOT.0000000000000850. Curr Opin Organ Transplant. 2021. PMID: 33595981 Review.
This review provides an updated account of the transplantation of hepatitis C virus (HCV), hepatitis B virus (HBV) and HIV-positive livers, with a specific focus on studies published in the last 18 months. ...
This review provides an updated account of the transplantation of hepatitis C virus (HCV), hepatitis B virus (HBV) and HIV-positive l …
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Mauz-Körholz C, et al. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9. Lancet Oncol. 2022. PMID: 34895479 Free PMC article. Clinical Trial.
Children and adolescents with newly diagnosed intermediate-stage (treatment group 2) and advanced-stage (treatment group 3) classical Hodgkin lymphoma who were younger than 18 years and stratified according to risk using Ann Arbor disease stages IIAE, IIB, IIBE, IIIA, IIIAE, IIIB …
Children and adolescents with newly diagnosed intermediate-stage (treatment group 2) and advanced-stage (treatment group 3) classical Hodgki …
Updated results on intestinal neuronal dysplasia (IND B).
Meier-Ruge WA, Ammann K, Bruder E, Holschneider AM, Schärli AF, Schmittenbecher PP, Stoss F. Meier-Ruge WA, et al. Eur J Pediatr Surg. 2004 Dec;14(6):384-91. doi: 10.1055/s-2004-821120. Eur J Pediatr Surg. 2004. PMID: 15630639 Review.
BACKGROUND: Intestinal neuronal dysplasia (IND B) is still a subject of controversy. The aim of this paper is to review the present state of knowledge on IND B. ...CONCLUSION: The diagnosis of IND B requires that biopsies are taken proximal to the ampulla rec …
BACKGROUND: Intestinal neuronal dysplasia (IND B) is still a subject of controversy. The aim of this paper is to review the present s …
177 results